Novel Anti-sema3a antibodies and uses thereof

Abstract

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present invention i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD) ≤ 50 nM, ≤ 20 nM, ≤10 nM, ≤1 nM, or ≤ 0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and / or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and / or dog Sema3A with a dissociation constant (KD) ≤ 50 nM, ≤ 20 nM, ≤10 nM, ≤1 nM, or ≤ 0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥ 60%, ≥ 70%, ≥ 80%, or ≥ 90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤ 10 nM, ≤ 5 nM, ≤ 2.5 nM, or ≤ 1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤ 50 nM, ≤ 25 nM, ≤ 10 nM, or ≤ 5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤ 1 nM, or ≤ 0.3 nM , ≤ 0,1 nM, ≤0,07 nM, ≤0,06nM and / or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.